The effect of glucagon‐like peptide‐1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta‐analysis

Mar 26, 2024Diabetes, obesity & metabolism

Glucagon-like peptide-1 receptor agonists and their effects on heart function and structure in people with and without type 2 diabetes

AI simplified

Abstract

GLP-1 receptor agonists improved the E/e' ratio by a mean difference of -0.73.

  • GLP-1 receptor agonists significantly reduced left ventricular mass by a mean difference of -3.86 g.
  • A reduction in left atrial volume of -8.20 mL was observed with GLP-1 receptor agonist treatment.
  • NT-proBNP levels decreased by a standardized mean difference of -0.27, indicating improved cardiac stress.
  • Patients showed an increase of 22.31 meters in the 6-minute walk test results, reflecting enhanced exercise capacity.
  • No significant change in left ventricular ejection fraction was noted, with a mean difference of +0.31%.

AI simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free